Search Results - "L., DEBONNETT"

O‐04: INCIDENCE OF VASO‐OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL‐WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP) by A., SILVA‐PINTO, R., COLOMBATTI, A., PASANISI, F., ARCIONI, L., DEBONNETT, W., SOLIMAN, R., SARKAR, R., CANÇADO

Get full text

S121: REDUCED RATE OF VASO‐OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL‐WORLD, MANAGED ACCESS PROGRAM (MAP) by Silva‐Pinto, A, Colombatti, R, Pasanisi, A, Arcioni, F, DeBonnett, L, Soliman, W, Sarkar, R, Cançado, R

Get full text

P1491: REAL‐WORLD INCIDENCE OF VASO‐OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP) by Silva‐Pinto, A. C., Colombatti, R., Pasanisi, A., Arcioni, F., DeBonnett, L., Soliman, W., Sarkar, R., Cançado, R. D.

Get full text

P‐010: TREATMENTS FOR SICKLE CELL DISEASE (SCD) AND THE HEALTHCARE PROFESSIONAL (HCP)–PATIENT RELATIONSHIP: HCP OPINIONS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY) by B., ANDEMARIAM, J., JAMES, C., MINNITI, B., INUSA, F., EL RASSI, A., NERO, C., TRIMNELL, M., ABBOUD, J., ARLET, R., COLOMBATTI, M., DE MONTALEMBERT, S., JAIN, W., JASTANIAH, E., NUR, M., PITA, L., DEBONNETT, T., BAILEY, O., RAJKOVIC‐HOOLEY, I., OSUNKWO

Get full text

P1467: HEALTHCARE PROFESSIONALS (HCP) OPINIONS ON TREATMENTS FOR SICKLE CELL DISEASE (SCD) AND THE HCP–PATIENT RELATIONSHIP: RESULTS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY) by Andemariam, B., James, J., Minniti, C., Inusa, B., El Rassi, F., Nero, A., Trimnell, C., Abboud, M. R., Arlet, J.‐B., Colombatti, R., Montalembert, M., Jain, S., Jastaniah, W., Nur, E., Pita, M., DeBonnett, L., Bailey, T., Rajkovic‐Hooley, O., Osunkwo, I.

Get full text

S131: REGIONAL ASSESSMENT OF THE EXPERIENCES OF HEALTHCARE PROFESSIONALS (HCPS) TREATING PATIENTS WITH SICKLE CELL DISEASE (SCD): THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY) by Osunkwo, I, Andemariam, B, Minniti, C, El Rassi, F, Nur, E, Nero, A, Colombatti, R, Montalembert, M, Abboud, M, Arlet, J, Jain, S, Jastaniah, W, Pita, M, Trimnell, C, DeBonnett, L, Bailey, T, Rajkovic‐Hooley, O, Inusa, B, James, J

Get full text

Adherence to the 2007 cystic fibrosis pulmonary guidelines: A national survey of CF care centers by Glauser, T.A., Nevins, P.H., Williamson, J.C., Abdolrasulnia, M., Salinas, G.D., Zhang, J., Debonnett, L., Riekert, K.A.

“…Objective To examine cystic fibrosis (CF) physician adherence to the 2007 CF Foundation (CFF) Pulmonary Guidelines for Chronic Medications. Specifically…”
Get full text

42 Tobramycin powder for inhalation is effective in advanced stage CF lung disease: the EAGER trial by Chiron, R, Geller, D.E, Angyalosi, G, Debonnett, L, Yadao, A, Bader, G, Konstan, M.W

Get full text

Tobramycin Powder for Inhalation for the Treatment of Cystic Fibrosis: Analysis of the RAMQ Data by Lachaine, J, Lapierre, M.E, Beauchemin, C, Balp, M.M, Calado, F, Debonnett, L, Desforges, J, Sagkriotis, A

Get full text

73 Real world evidence on inhaled tobramycin use in CF patients: analysis of the RAMQ data (Canada) by Lachaine, J, Lapierre, M.-È, Beauchemin, C, Angyalosi, G, Balp, M.-M, Calado, F, Debonnett, L, Desforges, J, Sagkriotis, A

Get full text

77 Long-term safety of tobramycin powder for inhalation in patients with cystic fibrosis: ETOILES study by Sommerwerck, U, Virella-Lowell, I, Angyalosi, G, Viegas, A.S, Iqbal, A, Wan, R, Debonnett, L

Get full text

75 Efficacy of inhaled antibiotics in CF patients with Pseudomonas aeruginosa (Pa) infection: a network meta-analysis (NMA) by Higashi, K, Janssen, K, Jansen, J, Angyalosi, G, Balp, M.-M, Calado, F, Debonnett, L, Sagkriotis, A, Döring, G, Elborn, J.S

Get full text

PRO82 IMPACT OF SICKLE CELL DISEASE SYMPTOMS ON PATIENTS' DAILY LIVES IN THE US - PATIENTS FROM THE SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY) by Osunkwo, I., Andemariam, B., Inusa, B., El Rassi, F., Nero, A., Minniti, C., Arlet, J.B., Colombatti, R., Jain, S., Jastaniah, W., Nur, E., Bailey, T., Rajkovic-Hooley, O., DeBonnett, L., James, J.

Get full text

A51 BRONCHIECTASIS: CLINICAL AND EPIDEMIOLOGIC STUDIES: Qbw251 Is A Safe And Efficacious Cftr Potentiator For Patients With Cystic Fibrosis by Kazani, S, Alcantara, J, Debonnett, L, Doucet, J, Jones, I, Kulmatycki, K, Machineni, S, Mostovy, L, Nicholls, I, Vegesna, R, Verheijen, J, Rowlands, D J

Get full text

S131: REGIONAL ASSESSMENT OF THE EXPERIENCES OF HEALTHCARE PROFESSIONALS (HCPS) TREATING PATIENTS WITH SICKLE CELL DISEASE (SCD): THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY) by Osunkwo, I, Andemariam, B, Minniti, C, El Rassi, F, Nur, E, Nero, A, Colombatti, R, de Montalembert, M, Abboud, M, Arlet, J, Jain, S, Jastaniah, W, Pita, M, Trimnell, C, DeBonnett, L, Bailey, T, Rajkovic-Hooley, O, Inusa, B, James, J

Get full text

PIN115 - Tobramycin Powder for Inhalation for the Treatment of Cystic Fibrosis: Analysis of the RAMQ Data by Lachaine, J., Lapierre, M.E., Beauchemin, C., Balp, M.M., Calado, F., Debonnett, L., Desforges, J., Sagkriotis, A.

Get full text

PB2300 IMPACT OF SICKLE CELL DISEASE FROM PATIENTS’ AND PHYSICIANS’ PERSPECTIVES: RESULTS FROM THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY) by Osunkwo, I., Abboud, M., Andemariam, B., Arlet, J.‐B., Colombatti, R., Montalembert, M., Rassi, F. El, Francis‐Gibson, B., Inusa, B., Jain, S., Jastaniah, W. J., Minniti, C., Nero, A., Nur, E., DeBonnett, L., Waller, J., James, J.

“…Background: Sickle cell disease (SCD) is the most common single‐gene disorder, affecting millions of people worldwide. SCD is common among people in Africa,…”
Get full text

Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: Results from the palivizumab outcomes registry by Parnes, Curt, Guillermin, Judith, Habersang, Rolf, Nicholes, Peggy, Chawla, Vijay, Kelly, Tammy, Fishbein, Judith, McRae, Patty, Goessler, Mary, Gatti, Antoinette, Calcagno, John A, Eki, Cheryl, Harris, Kristen A, Joyave, Joseph, McFarland, Kathy, Protter, Paul, Sullivan, Mary, Stanford, Allan, Lovett, Nancy, Ortiz, Marisol, Rojas, Sharon, Cyrus, Scott, Cyrus, Janell, Cohen, Stuart, Buchin, Debbie, Riordan, Linda, Zuniga, Monica, Shah, Rupa, Minard, Carmen, Quintin, Arden, Douglas, Glenda, van Houten, John, Freutner, Sharyn, Chartrand, Stephen, Nowatzke, Patsy, Romero, Jose, Rhodes, Torunn, Benoit, Michelle, Walter, Emmanuel, Walker, Leslie, DeBonnett, Laurie, Cross, Mia, Free, Teresa, Martin, Sharman, Shank, Karen, Guedes, Ben, Atkinson, Lee Ann, Halpin, George J, Rouse, Kathy, Hand, Ivan, Geiss, Donna, Marshall, James R, Burleson, Lois, Boland, Jim, Seybold, Kelsey, Hunter, Vicki, Unfer, Susan, Schmucker, Jackie, Gley, Margaret, Marcus, Michael, Thompson, Patricia, Milla, Paulino, Young, Connie, Zanni, Robert, Zinno, Virginia, Fetter-Zarzeka, Alexandra, Busey, Amanda, Sokunbi, Modupe A, Airington, Sherrie, Richard, Nancy, Muraligopal, Vellore, Lewis, Stephanie, Weber, F Thomas, Giordano, Beverly P, Linehan, Denise, Roach, Jane, Davis, Randle, Rzepka, Andrew A, Booth, Teri, Smeltzer, David, Walsh, Jeanne, Arispe, Emilio, Rowley, Rhonda, Bolling, Christopher, Botts, Tanya, Haskett, Kateri, Raby, Deana, Batiz, Evelyn, Gelfand, Andrew, Farrell, Lynn, Butler, Stephen, Colby, Linda, Schochet, Peter, Bentler, Julie, Hirsch, David, Wilkinson, Lisa, Aaronson, Allen, Bennett, Eleanora, Wingate, Julie, Quinn, Dawn

“…The objective of the Registry was to characterize the population of infants receiving prophylaxis for respiratory syncytial virus (RSV) disease by describing…”
Get full text